Clinical Trial Update: A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator [Phase 2]

View source ↗

Summary

Phase 2 placebo-controlled study of INT131 Besylate in Type 2 diabetes mellitus to evaluate safety and efficacy, with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• INT131 Besylate (INT131 besylate)

Snippet

Sponsor: InteKrin Therapeutics, Inc. | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED | Results posted: 2010-09-13